175 related articles for article (PubMed ID: 11098880)
1. Commentary: considerations on the pharmacological treatment of compulsions and stereotypies with serotonin reuptake inhibitors in pervasive developmental disorders.
Gordon CT
J Autism Dev Disord; 2000 Oct; 30(5):437-8. PubMed ID: 11098880
[No Abstract] [Full Text] [Related]
2. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.
McDougle CJ; Kresch LE; Posey DJ
J Autism Dev Disord; 2000 Oct; 30(5):427-35. PubMed ID: 11098879
[TBL] [Abstract][Full Text] [Related]
3. Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram.
Habermeyer B; Fuhr P
Pharmacopsychiatry; 2007 Mar; 40(2):87. PubMed ID: 17447184
[No Abstract] [Full Text] [Related]
4. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.
King BH; Hollander E; Sikich L; McCracken JT; Scahill L; Bregman JD; Donnelly CL; Anagnostou E; Dukes K; Sullivan L; Hirtz D; Wagner A; Ritz L;
Arch Gen Psychiatry; 2009 Jun; 66(6):583-90. PubMed ID: 19487623
[TBL] [Abstract][Full Text] [Related]
5. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F
Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412
[TBL] [Abstract][Full Text] [Related]
6. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Okada T
Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
[No Abstract] [Full Text] [Related]
7. Fluoxetine for OCD after brain injury.
Stengler-Wenzke K; Müller U
Am J Psychiatry; 2002 May; 159(5):872. PubMed ID: 11986149
[No Abstract] [Full Text] [Related]
8. Treating obsessive-compulsive disorder.
Long K; Long R
Nurse Pract Forum; 1995 Sep; 6(3):136-7. PubMed ID: 7549614
[No Abstract] [Full Text] [Related]
9. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
Giger JN; Davidhizar R; Poole VL
J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
[No Abstract] [Full Text] [Related]
11. Predictors of treatment response in pediatric obsessive-compulsive disorder.
Grados MA; Ginsburg GS; Drake KL; Kingery JN
J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):573-574. PubMed ID: 19395904
[No Abstract] [Full Text] [Related]
12. Psychopharmacology of obsessive-compulsive disorder in Tourette syndrome.
King RA; Riddle MA; Goodman WK
Adv Neurol; 1992; 58():283-91. PubMed ID: 1414634
[No Abstract] [Full Text] [Related]
13. Obsessive-compulsive disorder following cavernous sinus thrombosis.
Garyfallos G; Papazisis G; Katsigiannopoulos K; Bozikas VP; Adamopoulou A
J Neuropsychiatry Clin Neurosci; 2009; 21(4):473-4. PubMed ID: 19996263
[No Abstract] [Full Text] [Related]
14. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
Dinca O; Paul M; Spencer NJ
J Psychopharmacol; 2005 Sep; 19(5):521-32. PubMed ID: 16166190
[TBL] [Abstract][Full Text] [Related]
15. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Dwivedi S; Pavuluri M; Heidenreich J; Wright T
J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
[No Abstract] [Full Text] [Related]
16. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
[No Abstract] [Full Text] [Related]
17. Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder.
Delorme R; Betancur C; Wagner M; Krebs MO; Gorwood P; Pearl P; Nygren G; Durand CM; Buhtz F; Pickering P; Melke J; Ruhrmann S; Anckarsäter H; Chabane N; Kipman A; Reck C; Millet B; Roy I; Mouren-Simeoni MC; Maier W; Råstam M; Gillberg C; Leboyer M; Bourgeron T
Mol Psychiatry; 2005 Dec; 10(12):1059-61. PubMed ID: 16088327
[No Abstract] [Full Text] [Related]
18. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Wolmarans de W; Brand L; Stein DJ; Harvey BH
Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
Besiroglu L; Çetinkaya N; Selvi Y; Atli A
Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
